Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 2014. The report details the announcement of headline results from a Phase III clinical study regarding the combination therapy of Tafinlar (dabrafenib) and Mekinist (trametinib) for the treatment of metastatic melanoma.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused exclusively on clinical trial outcomes and safety information rather than financial performance.
Material Changes and Clinical Results
The primary material update concerns the COMBI-d Phase III study (NCT01584648), which compared the combination of dabrafenib and trametinib against dabrafenib monotherapy in patients with BRAF V600E or K mutation-positive unresectable or metastatic melanoma.
- Primary Endpoint: The study met its primary endpoint of Progression Free Survival (PFS) with a p-value of less than 0.05.
- Study Population: The trial randomized 423 patients across investigative sites in Australia, Europe, North America, and South America.
- Comparative Results: PFS, response rate, and interim overall survival for the combination arm were consistent with previous Phase I/II data. However, PFS in the single-agent dabrafenib arm was greater than in prior studies, resulting in a more modest difference in PFS between the treatment arms compared to earlier phases.
- Adverse Events: The most commonly reported adverse events (>20%) in the combination arm included pyrexia, fatigue, nausea, headache, chills, diarrhoea, arthralgia, rash, hypertension, and vomiting.
Outlook, Risks, and Management Commentary
Dr. Rafael Amado, Senior Vice President of Oncology R&D, stated that these results, combined with anticipated data later in 2014 from the COMBI-v study (comparing the combination to vemurafenib), will expand the evidence base for the safety and efficacy of the combination therapy.
Regulatory Status: The combination use of Tafinlar and Mekinist is currently approved only in the US and is not approved elsewhere globally.
Material Risks and Safety Warnings: The filing highlights significant safety risks associated with the combination therapy compared to monotherapy:
- New Primary Malignancies: Increased incidence of basal cell carcinoma (9% vs 2%) and cutaneous squamous cell carcinoma (7% vs 19% for monotherapy).
- Haemorrhage: Increased incidence and severity (16% vs 2%), including fatal intracranial haemorrhage in 4% of combination patients.
- Venous Thromboembolic Events: Increased incidence of DVT and pulmonary embolism (7% vs 0%), with one fatal pulmonary embolism (2%).
- Cardiomyopathy: Occurred in 9% of combination patients versus 0% in monotherapy.
- Febrile Reactions: Fever incidence was 71% in the combination arm versus 26% in the monotherapy arm. Serious febrile reactions with hypotension occurred in 25% vs 2%.
- Ocular Toxicities: Risks include Retinal Vein Occlusion (RVO), Retinal Pigment Epithelial Detachment (RPED), and uveitis.
Investor Verification Checklist
- Verify the timeline for the anticipated results of the COMBI-v study comparing the combination to vemurafenib.
- Confirm the regulatory submission status for the combination therapy in markets outside the US.
- Review the full safety data regarding the increased incidence of haemorrhage, cardiomyopathy, and febrile reactions in the context of the drug's risk-benefit profile.
- Monitor upcoming scientific meetings for the presentation of full study results.